Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (210)
  • Open Access

    ARTICLE

    Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo

    Leonard Lothstein*, Judith Soberman, Deanna Parke*, Jatin Gandhi*, Trevor Sweatman, Tiffany Seagroves*

    Oncology Research, Vol.28, No.5, pp. 451-465, 2020, DOI:10.3727/096504020X15898794315356

    Abstract Triple-negative breast cancer (TNBC) is unresponsive to antiestrogen and anti-HER2 therapies, requiring the use of cytotoxic drug combinations of anthracyclines, taxanes, cyclophosphamide, and platinum compounds. Multidrug therapies achieve pathological cure rates of only 20–40%, a consequence of drug resistance and cumulative dose limitations necessitated by the reversible cardiotoxic effects of drug therapy. Safer and more effective treatments for TNBC are required to achieve durable therapeutic responses. This study describes the mechanistic analyses of the novel anthracycline, pivarubicin, and its in vivo efficacy against human primary TNBC. Pivarubicin directly activates PKCd, triggers rapid mitochondrial-dependent apoptosis, and… More >

  • Open Access

    ARTICLE

    MicroRNA-548m Suppresses Cell Migration and Invasion by Targeting Aryl Hydrocarbon Receptor in Breast Cancer Cells

    WM Farhan Syafiq B. WM Nor*†, Ivy Chung‡§, Nur Akmarina B. M. Said

    Oncology Research, Vol.28, No.6, pp. 615-629, 2020, DOI:10.3727/096504020X16037933185170

    Abstract Breast cancer is the most commonly diagnosed cancer among women and one of the leading causes of cancer mortality worldwide, in which the most severe form happens when it metastasizes to other regions of the body. Metastasis is responsible for most treatment failures in advanced breast cancer. Epithelial–mesenchymal transition (EMT) plays a significant role in promoting metastatic processes in breast cancer. MicroRNAs (miRNAs) are highly conserved endogenous short noncoding RNAs that play a role in regulating a broad range of biological processes, including cancer initiation and development, by functioning as tumor promoters or tumor suppressors.… More >

  • Open Access

    ARTICLE

    miR-142-5p Inhibits Cell Invasion and Migration by Targeting DNMT1 in Breast Cancer

    Hui Li*1, Han-Han Li†1, Qian Chen‡1, Yu-Yang Wang, Chang-Chang Fan, Yuan-Yuan Duan, You Huang, Hui-Min Zhang, Jia-Peng Li, Xiao-Yu Zhang, Yuan Xiang, Chao-Jiang Gu, Li Wang§, Xing-Hua Liao, Tong-Cun Zhang‡¶

    Oncology Research, Vol.28, No.9, pp. 885-897, 2020, DOI:10.3727/096504021X16274672547967

    Abstract Abnormal cell proliferation caused by abnormal transcription regulation mechanism seems to be one of the reasons for the progression of breast cancer and also the pathological basis. MicroRNA-142-5p (miR-142-5p) is a low-expressed miRNA in breast cancer. The role of MKL-1’s regulation of DNMT1 in breast cancer cell proliferation and migration is still unclear. MKL-1 (myocardin related transcription factor A) can bind to the conserved cis-regulatory element CC (A/T) 6GG (called CarG box) in the promoter to regulate the transcription of miR-142-5p. The expressions of miR-142-5p and MKL-1 are positively correlated. In addition, it has been More >

  • Open Access

    ARTICLE

    miR-325-3p Promotes the Proliferation, Invasion, and EMT of Breast Cancer Cells by Directly Targeting S100A2

    Huiling Wang*, Xin Hu, Feng Yang, Hui Xiao*

    Oncology Research, Vol.28, No.7-8, pp. 731-744, 2020, DOI:10.3727/096504020X16100888208039

    Abstract This study was designed to investigate the precise mechanisms of miR-325-3p/S100A2 axis in breast cancer (BC). In this study, we found that the level of miR-325-3p was dramatically increased in BC tissues and cell lines, and the expression of S100A2 was significantly decreased. Also, the high level of miR-325-3p was closely associated with low expression of S100A2 in BC tissues. Moreover, introduction of miR-325-3p significantly promoted proliferation, invasion, and EMT of BC cells. Bioinformatics analysis predicted that the S100A2 was a potential target gene of miR-325-3p. Luciferase reporter assay demonstrated that miR-325-3p could directly target More >

  • Open Access

    ARTICLE

    MicroRNA-152 Inhibits Cell Proliferation, Migration, and Invasion in Breast Cancer

    Adilijiang Maimaitiming*, Ailijiang Wusiman, Abulajiang Aimudula, Xuekelaiti Kuerban*, Pengcheng Su*

    Oncology Research, Vol.28, No.1, pp. 13-19, 2020, DOI:10.3727/096504019X15519249902838

    Abstract The aim of the present study was to investigate the roles of microRNA-152 (miR-152) in the initiation and progression of breast cancer. The expression level of miR-152 was detected in human breast cancer tissue and a panel of human breast cancer cell lines using qRT-PCR. Results found that miR-152 expression was significantly downregulated in breast cancer tissue samples compared to adjacent noncancerous tissues as well as in breast cancer cell lines. Overexpression of miR-152 significantly suppressed breast cancer cell proliferation, migration, and invasion. Luciferase reporter assay results found that ROCK1 is a direct and functional More >

  • Open Access

    ARTICLE

    Chaperone-mediated autophagy targeting chimeras (CMATAC) for the degradation of ERα in breast cancer

    JUN ZHANG, YEHONG HUANG, WENZHUO LIU, LULU LI, LIMING CHEN*

    BIOCELL, Vol.44, No.4, pp. 591-595, 2020, DOI:10.32604/biocell.2020.011642 - 24 December 2020

    Abstract Estrogen receptor alpha (ERα/ESR1) is overexpressed in over half of all breast cancers and is considered a valuable therapeutic target in ERα positive breast cancer. Here, we designed a membrane-permeant Chaperonemediated Autophagy Targeting Chimeras (CMATAC) peptide to knockdown endogenous ERα protein through chaperone-mediated autophagy. The peptide contains a cell membrane-penetrating peptide (TAT) that allows the peptide to by-pass the plasma membrane, an αI peptide as a protein-binding peptide (PBD) that binds specifically to ERα, and CMA-targeting peptide (CTM) that targeting chaperone-mediated autophagy. We validated that ERα targeting peptide was able to target and degrade ERα More >

  • Open Access

    ARTICLE

    RETRACTED: LncRNA TUG1 Targets miR-222-3p to Take Part in Proliferation and Invasion of Breast Cancer Cells

    Yuqin Xie1, Shuang Deng1, Qian Deng2, Jiudong Xu*

    Oncologie, Vol.22, No.3, pp. 179-188, 2020, DOI:10.32604/Oncologie.2020.012544

    Abstract This study aimed to explore LncRNA TUG1 targeted miR-222-3p in the proliferation and invasion of breast cancer (BC) cells. Seventy-six BC patients admitted to our hospital and 62 health check-ups at the same time were selected as the research objects. Among them, the former was seen as the observation group (OG), and the latter was considered as the control group (CG). The clinical significance of LncRNA TUG1 and miR-222-3p in BC was detected. Human BC cell MCF7 and normal human breast epithelial cell MCF-10A were purchased. After cells were transfected with LncRNA TUG1 and miR-222-3p,… More >

  • Open Access

    CASE REPORT

    Double Heterozygosity in the BRCA1/2 Genes in a Turkish Patient with Bilateral Breast Cancer: A Case Report

    Neslihan Duzkale1,*, Nilnur Eyerci2

    Oncologie, Vol.22, No.3, pp. 161-166, 2020, DOI:10.32604/oncologie.2020.014116

    Abstract BRCA1 and BRCA2 tumor suppressor genes are responsible for a quarter of hereditary breast cancers. Double heterozygous (DH) pathogenic variant carrier status in these genes is an extremely rare condition, especially in non-Askenazi individuals. We report a woman patient with bilateral breast cancer that carries DH disease-causing variants in BRCA1/2 genes. The 45-year-old patient who was followed up with the diagnosis of metachronous bilateral breast cancer was diagnosed with cancer at the age of 39 and 43, respectively. BRCA1/2 genes of the patient were evaluated using Next-Generation Sequencing. In the patient, the c.2800C>T (p.Gln934Ter) pathogenic variant in BRCA1More >

  • Open Access

    ARTICLE

    Prognostic and Predictive Significance of Eukaryotic Elongation Factor 1D (eEF1D) in Breast Cancer: A Potential Marker of Response to Endocrine Therapy

    Burcu BİTERGE SÜT1,*, Ayşe İKİNCİ KELEŞ2

    Oncologie, Vol.22, No.3, pp. 147-154, 2020, DOI:10.32604/oncologie.2020.014449

    Abstract Components of the protein synthesis machinery are subjected to alterations in cancer cells. eEF1D gene, which lies within the frequently amplified 8q24 locus, is one of the subunits of the human eukaryotic elongation factor complex. This study aimed to evaluate the prognostic and predictive significance of eEF1D in breast cancer using in silico analysis tools. For this purpose, we analyzed genomic alterations of the eEF1D gene using TCGA datasets via cBioPortal. Histopathological analysis was performed on patient tissue images obtained from cBioPortal and the Human Protein Atlas. Survival analysis was carried out using the KM… More >

  • Open Access

    ARTICLE

    miR-1284 Inhibits the Growth and Invasion of Breast Cancer Cells by Targeting ZIC2

    Pengcheng Zhang*, Fang Yang, Qin Luo, Daxue Yan§, Shengrong Sun*

    Oncology Research, Vol.27, No.2, pp. 253-260, 2019, DOI:10.3727/096504018X15242763477504

    Abstract miR-1284 has been reported to inhibit tumor growth in some human cancers, including lung cancer, ovarian cancer, and gastric cancer. Whether it regulates breast cancer progression remains elusive. In this study, we found that miR-1284 was downregulated in breast cancer tissues and cell lines compared to normal control cells. Moreover, we showed that overexpression of miR-1284 significantly inhibited the proliferation, migration, and invasion of breast cancer cells while promoting apoptosis. In terms of mechanism, we found that transcription factor ZIC2 was a target of miR-1284 in breast cancer cells. Through the luciferase reporter assay, we More >

Displaying 161-170 on page 17 of 210. Per Page